Zacks Investment Research cut shares of Axovant Sciences Ltd. (NYSE:AXON) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “

Several other analysts also recently issued reports on AXON. Oppenheimer Holdings, Inc. restated a buy rating on shares of Axovant Sciences in a report on Wednesday, March 22nd. Piper Jaffray Companies restated an overweight rating and set a $32.00 price objective on shares of Axovant Sciences in a report on Wednesday, April 12th. Jefferies Group LLC reaffirmed a buy rating and set a $31.00 target price on shares of Axovant Sciences in a research note on Tuesday, April 18th. CIBC lifted their target price on Axovant Sciences from $30.00 to $33.00 and gave the company a neutral rating in a research note on Tuesday, April 18th. Finally, Cowen and Company reaffirmed an outperform rating and set a $30.00 target price (up previously from $22.00) on shares of Axovant Sciences in a research note on Tuesday, June 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $28.50.

Axovant Sciences (NYSE:AXON) traded up 0.7891% during midday trading on Tuesday, hitting $24.4716. 181,243 shares of the company traded hands. The company’s market cap is $2.63 billion. Axovant Sciences has a 12-month low of $11.01 and a 12-month high of $26.49. The stock has a 50 day moving average price of $22.40 and a 200-day moving average price of $17.00.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings data on Tuesday, June 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. Analysts expect that Axovant Sciences will post ($2.20) EPS for the current year.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/axovant-sciences-ltd-axon-cut-to-sell-at-zacks-investment-research/1445448.html.

Several large investors have recently made changes to their positions in the stock. Primecap Management Co. CA boosted its stake in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock valued at $43,011,000 after buying an additional 2,159,428 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock valued at $3,124,000 after buying an additional 197,600 shares during the last quarter. C WorldWide Group Holding A S purchased a new stake in shares of Axovant Sciences during the first quarter valued at approximately $1,637,000. Candriam Luxembourg S.C.A. boosted its stake in shares of Axovant Sciences by 77.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 160,000 shares of the biotechnology company’s stock valued at $2,391,000 after buying an additional 70,000 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Axovant Sciences during the fourth quarter valued at approximately $508,000. 94.54% of the stock is owned by institutional investors and hedge funds.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.